Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Prestige Consumer Healthcare (PBH) Cash & Equivalents (2016 - 2025)

Prestige Consumer Healthcare (PBH) has 16 years of Cash & Equivalents data on record, last reported at $62.4 million in Q4 2025.

  • For Q4 2025, Cash & Equivalents rose 22.6% year-over-year to $62.4 million; the TTM value through Dec 2025 reached $62.4 million, up 22.6%, while the annual FY2025 figure was $97.9 million, 110.64% up from the prior year.
  • Cash & Equivalents reached $62.4 million in Q4 2025 per PBH's latest filing, down from $119.1 million in the prior quarter.
  • Across five years, Cash & Equivalents topped out at $163.6 million in Q2 2021 and bottomed at $21.0 million in Q4 2021.
  • Average Cash & Equivalents over 5 years is $64.5 million, with a median of $53.1 million recorded in 2023.
  • The widest YoY moves for Cash & Equivalents: up 310.88% in 2022, down 78.08% in 2022.
  • A 5-year view of Cash & Equivalents shows it stood at $21.0 million in 2021, then surged by 310.88% to $86.4 million in 2022, then decreased by 26.34% to $63.6 million in 2023, then fell by 20.03% to $50.9 million in 2024, then increased by 22.6% to $62.4 million in 2025.
  • Per Business Quant database, its latest 3 readings for Cash & Equivalents were $62.4 million in Q4 2025, $119.1 million in Q3 2025, and $139.5 million in Q2 2025.